Business context and reporting period
Aegon Ltd. filed this Form 6-K on October 8, 2026, reporting that its Extraordinary General Meeting of Shareholders approved proposals for the company’s redomiciliation to the United States and an Omnibus Incentive Plan.
Financial and operating metrics
The filing reports no revenue, profit, cash flow, margin, debt, liquidity, or other current-period financial results. It does not provide a clear financial estimate of the redomiciliation or incentive plan’s costs or benefits.
Material developments
- Aegon expects to proceed on October 15, 2026, with the repurchase of all outstanding Common Shares B held by Vereniging Aegon in exchange for common shares with equal voting rights on a 40-to-1 basis. The interim bye-laws approved at the EGM are expected to take effect upon completion.
- Vereniging Aegon is to be renamed Vereniging Aegon Americas and is expected to retain an approximately 18.4% stake in Aegon. Its Dutch charitable activities are to continue through a newly established Stichting Aegon Fonds Nederland.
- Aegon announced a Capital Markets Day for December 9, 2027, in New York City.
- Aegon previously announced an agreement to sell Aegon UK on April 15, 2026, with completion expected around the end of 2026.
Outlook, risks, and contingencies
The company expects to proceed with the redomiciliation, but completion and anticipated benefits are uncertain. Aegon cautions that forward-looking statements are subject to risks, including failure to satisfy transaction conditions, delays, effects on employees and operations, and potential effects on trading, liquidity, and the price of its securities. Other cited risks include market, interest-rate, currency, credit, regulatory, solvency, operational, cyber, litigation, and transaction risks. The filing gives no new financial guidance.
Key facts for investors to verify
- Whether the October 15 share transaction is completed and the interim bye-laws take effect.
- Subsequent details on the US redomiciliation, including timing, conditions, and expected costs or benefits.
- Completion timing and terms of the Aegon UK sale.
- Any later financial disclosures on the Omnibus Incentive Plan or related share arrangements.